

Study of Placental Growth Factor as a Novel Diagnostic Biomarker for Ectopic Pregnancy

Thesis

Submitted for Partial Fulfillment of M.D. Degree in Obstetrics and Gynecology

Вy

Enas Mohamed Tamer Masoud

M.B.,B.Ch., Dubai Medical College for Girls (2003) M.Sc. Obstetrics and Gynecology – Ain Shams University (2009)

Supervisors

Prof. Essam-Eldin Mohamed Ammar

Professor of Obstetrics and Gynecology Faculty of Medicine, Ain Shams University

Prof. Gamal Farag Mostafa

Professor of Obstetrics and Gynecology Faculty of Medicine, Ain Shams University

Asst. Prof. Tarek Aly Raafat

Assistant Professor of Obstetrics and Gynecology Faculty of Medicine, Ain Shams University

Prof. Mona Mohamed Zaki

Professor of Clinical and Chemical Pathology Faculty of Medicine, Ain Shams University

> Faculty of Medicine Ain Shams University Cairo 2014

ACKNOWLEDGMENTS

Thanks are all to **ALLAH**, the Compassionate and the Merciful, for helping me finish this work, and for blessing me throughout my life by His Compassion and Generosity.

Words fail to express my deepest gratefulness to **Professor Essam-Eldin Mohamed Ammar**, Professor of Obstetrics and Gynaecology, Ain Shams University, for his continuous support, guidance, keen education and his fatherly advice which have been of great help in performing this work.

I would like to express my sincerest wishes and deep gratitude for **Professor Gamal Farag Mostafa**, Professor of Obstetrics and Gynecology, Ain Shams University, for his generous efforts throughout this work, his meticulous correction and guidance, his patience and endless support.

I would like to express my appreciation to **Dr. Tareq Aly Raafat**, Assistant professor of Obstetrics and Gynecology, Ain Shams University, for his continuous supervision and guidance throughout the work.

I am also deeply grateful to **Professor Mona Mohamed Zaki**, Professor of Clinical and Chemical Pathology, Ain Shams University, for her guidance and support throughout the laboratory and technical parts of this work.

Thanks fail to express my deepest gratitude and indebtedness to my Parents. Because of their continuous help, support and loving advice I have reached this far. To Them, I humbly dedicate this work. Also, I am deeply indebted to my husband and my son for their great support, encouragement and patience all along. I would like to express my deepest gratitude to my brothers and to my whole family, who always support me throughout my life.

I will not forget to express my thanks to the staff of Ain Shams University Maternity Hospital and the staff of laboratories of Ain Shams University Hospitals for their help throughout the clinical part of this work. I will not either forget to thank the patients who accepted the participation in this study, and made it possible to complete this work.

CONTENTS

	Page
ACKNOWLEDGMENTS	ii
CONTENTS	iii
LIST OF FIGURES	ix
LIST OF TABLES	xi
LIST OF ABBREVIATIONS	xiv
PROTOCOL	xxi
INTRODUCTION	1
AIM OF THE WORK	11
REVIEW OF LITERATURE	12
1. ECTOPIC PREGNANCY	12
1.1 Definition of Ectopic Pregnancy	12
1.2 History of Ectopic Pregnancy	15
1.3 Epidemiology of Ectopic Pregnancy	18
1.3.1 Increasing Ectopic Pregnancy Rates	28
1.3.2Maternal Mortality from Ectopic	
Pregnancy	31
1.3.3Incidence and Maternal Mortality of	
Ectopic Pregnancy in Developing	
Countries	36
1.4 Sites of Ectopic Pregnancy	46
1.4.1 Tubal Pregnancy	48
1.4.2 Abdominal Pregnancy	52
1.4.3 Broad Ligament Pregnancy	58

1.4.4 Multifetal Ectopic Pregnancy	58
1.4.4.1 Heterotropic Ectopic Pregnancy	58
1.4.4.2 Multifetal Tubal Pregnancy	59
1.4.5 Ovarian Pregnancy	60
1.4.6 Cervical Pregnancy	62
1.4.7 Cesarean Scar Pregnancy (CSP)	66
1.4.8 Other Sites of Ectopic Pregnancy	69
1.5 Risk Factors for Ectopic Pregnancy	70
1.5.1Tubal Damage Secondary to	
Inflammation	76
1.5.1.1Pelvic Inflammatory Disease (PID)	76
1.5.1.1.1 Chlamydia trachomatis	78
1.5.2 Prior Tubal Surgery	83
1.5.3Previous History of Ectopic	
Pregnancy	86
1.5.4Assisted Reproductive Technologies	
(ART)	88
1.5.5Contraceptive Use	91
1.5.5.1 Contraceptive Devices	92
1.5.5.2 Oral Contraceptives	94
1.5.6 Developmental Anomalies	95
1.5.7 Cigarette Smoking	96
1.5.8 Increasing Maternal Age	99
1.5.9 Previous Cesarean Delivery	100
1.5.10 Other Lifestyle Factors	101
1.6 Pathologic Features of Tubal	
Pregnancy	104

1.6.1 Gross Findings	104
1.6.2 Microscopic Findings	105
48D (I	107
1.7 Pathogenesis of Ectopic Pregnancy	107
1.7.1 Embryo-Tubal Transport	113
1.7.1.1 Tubal Smooth Muscle Contractility	
and Ciliary Beat Activity	113
1.7.1.2 Nitric Oxide (NO) and Nitric Oxide	
Synthase (NOS)	114
1.7.1.3 Interstitial Cells of Cajal (ICC)	115
1.7.1.4 Prokineticins (PROK)	116
1.7.1.5 Endocannabinoids (CB)	118
1.7.2 The Tubal Environment	120
1.7.2.1 Sex Steroid Hormone Receptors	120
1.7.2.2 Uteroglobin	125
1.7.2.3 Interleukin-1, Interleukin-8 and	
Interleukin-6	126
1.7.2.4 Leukemia Inhibitory Factor (LIF)	128
1.7.2.5 Homebox Protein A10 (HOXA10)	130
1.7.2.6 Integrins	132
1.7.2.7 Vascular Endothelial Growth	
Factor (VEGF) and Placental	
Growth Factor (PIGF)	133
1.7.2.8 Mucin 1 (MUC1)	135
1.7.2.9 Trophinin	136
1.7.2.10 Activins	137
1.7.2.11 The Innate Immune System	140
1.7.2.11.1 Intra-Epithelial Lymphocytes	140
1.7.2.11.2 Macrophages	140

1.7.2.11.3 Natural Anti-Microbial Peptides.	141
1.8 Clinical Presentation of Ectopic Pregnancy	143
1.8.1 Symptoms and Signs	146
1.9 Biochemical Diagnosis of Ectopic	
Pregnancy	151
1.9.1 Human Chorionic Gonadotropin (β-	
hCG)	152
1.9.2 Serum Progesterone	162
1.9.3 Novel Serum Biomarkers	165
1.9.3.1 Pregnancy-Associated Plasma	
Protein-A (PAPP-A)	169
1.9.3.2 Pregnancy-Specific β-1-	
Glycoprotein (Schwangerschaft	
Protein)	170
1.9.3.3 Human Placental Lactogen (hPL)	171
1.9.3.4 Activin A	172
1.9.3.5 α-Fetoprotein (AFP) and Cell-Free	
Fetal DNA	174
1.9.3.6 A Disintegrin and	
Metalloprotease-12 (ADAM-12)	176
1.9.3.7 Nucleic Acid Markers	177
1.9.3.8 Inhibin A	178
1.9.3.9 Relaxin and Renin	180
1.9.3.10 Creatine Kinase (CK)	181
1.9.3.11 Myoglobin and Smooth Muscle	
Heavy-Chain Myosin	183

	1.9.3.12 Vascular Endothelial Growth	
	Factor (VEGF)	184
	1.9.3.13 Placental like Growth Factor	
	(PlGF)	189
	1.9.3.14 Leukemic Inhibitory Factor (LIF)	190
	1.9.3.15 Glycodelin (Placental Protein-14)	191
	1.9.3.16 Mucin-1 (MUC1)	192
	1.9.3.17 Adrenomedullin	193
	1.9.3.18 Interleukin-2 Receptors (IL2R),	
	Interleukin-6 (IL-6), Interleukin-8	
	(IL-8) and Tumor Necrosis Factor	
	(TNF)	193
	1.9.3.19 Cancer Antigen 125 (CA-125)	194
2.	PLACENTAL GROWTH FACTOR	197
_,	PLACENTAL GROWTH FACTOR JECTS AND METHODS	197218
_,		
_,	JECTS AND METHODS	218
_,	JECTS AND METHODS Study Design Study Approval	218 218
_,	Study Design Study Approval Study Groups	218 218 218
_,	JECTS AND METHODS Study Design Study Approval	218 218 218 219
_,	IECTS AND METHODS Study Design Study Approval Study Groups Study Sample Size	218 218 218 219 219
_,	IECTS AND METHODS Study Design Study Approval Study Groups Study Sample Size Inclusion Criteria Exclusion Criteria	218 218 218 219 219 220 220
_,	IECTS AND METHODS Study Design Study Approval Study Groups Study Sample Size Inclusion Criteria Exclusion Criteria Subjects' Recruitment	218 218 219 219 220 220 220
_,	Study Design Study Approval Study Groups Study Sample Size Inclusion Criteria Exclusion Criteria Subjects' Recruitment Ethics and Patients' Rights	218 218 219 219 220 220 220 221
_,	Study Design Study Approval Study Groups Study Sample Size Inclusion Criteria Exclusion Criteria Subjects' Recruitment Ethics and Patients' Rights Methods	218 218 219 219 220 220 220 221 221
_,	Study Design Study Approval Study Groups Study Sample Size Inclusion Criteria Exclusion Criteria Subjects' Recruitment Ethics and Patients' Rights	218 218 219 219 220 220 220 221

[B] Immunoassay Procedure	223
o Principle Of The Assay	224
o Reagents	224
O Reagent Preparation	225
o Assay Procedure	227
o Calculation of Results	228
Participants' Data Recording	229
• Participants' Follow up	230
Outcome Measures	231
Statistical Methodology	231
• Addendum-1 (Informed Consent Forms)	234
• Addendum-2 (Participant's Record	
Form)	248
RESULTS	251
DISCUSSION	263
CONCLUSION AND RECOMMENDATIONS	278
SUMMARY	280
REFRENCES	285
ADARIC SUMMADV	

LIST OF FIGURES

Figure	<u>Title</u>	Page
No.		
1	Case-fatality rate and incidence of	
	ectopic pregnancy for the United States,	
	1980–1992	23
2	Sites of Ectopic Pregnancy	47
3	Left ampullary fallopian tube ectopic	
	pregnancy	49
4	Cornual ectopic pregnancy	51
5	Ruptured ampullary early tubal	
	pregnancy	51
6	Early abdominal ectopic pregnancy	54
7	Abdominal pregnancy at term	56
8	Coronal view of T2-weighted single	
	shot fast spin echo (SSFSE) MRI of an	
	18 week extrauterine pregnancy	57
9	Ovarian ectopic pregnancy	61
10	A. Transvaginal sonography, sagittal	
	view of a cervical pregnancy, B.	
	Transverse view of the cervical	
	pregnancy	65
11	Transvaginal sonogram sagittal view	
	shows a uterus with a cesarean scar	
	pregnancy (CSP)	68
12	Hysterectomy specimen with a cesarean	
	scar pregnancy is transversely sectioned	
	at the level of the uterine isthmus and	

	through the gestational sac	69
13	Gross Picture of Tubal ectopic	
	pregnancy	104
14	Schematic diagram summarizing the	
	potential factors contributing to the	
	development of tubal ectopic	
	pregnancy	110
15	Immunohistochemistry for CB1 protein	
	expression in Fallopian tube	119
16	The nonpregnant Fallopian tube	121
17	The tubal implantation site	123
18	Change in the hCG level in intrauterine	
	pregnancy, ectopic pregnancy, and	
	spontaneous abortion	159
19	Serum biomarker themes	168
20	Diagram illustrating the placenta,	
	amniotic and coelomic cavities, yolk sac	
	and embryo at 7–10 weeks of gestation	205
21	Hypothesis for the hypoxic- and	
	estrogen-dependent regulation of	
	VEGF/PIGF expression, secretion, and	
	signaling pathways that are possibly	
	involved in the pathophysiology of tubal	
	EP	213
22	The stock solution was used to produce	
	a dilution series	227
23	ROC curve analysis showing the	
	diagnostic performance of PIGF for	
	discriminating cases from controls	262

LIST OF TABLES

<u>Table</u>	<u>Title</u>	Page
No.		
1	Numbers of deaths from ectopic	
	pregnancies and rates per 100 000	
	estimated ectopic pregnancies; England	
	and Wales 1988-90 and UK: 1991-	
	2008	34
2	Joint distribution of causes of maternal	
	deaths	35
3	The extrapolated statistics of ectopic	
	pregnancy in the Middle East	43
4	Maternal mortality and ectopic	
	pregnancy: main results in studies	
	performed in African developing	
	countries	45
5	Some reported risk factors for ectopic	
	pregnancy	72
6	Risk factors for ectopic pregnancy	73
7	Risk factors for ectopic pregnancy,	
	categorized into high, moderate and low	
	risk factors	74
8	Ectopic pregnancy risk scale	75
9	Summary of ectopic pregnancy after	
	tubal surgery	84
10	Summary of maternally controlled	
	factors; in the development of ectopic	
	pregnancy	111

11	Summary of embryo controlled factors;	
	in the development of ectopic	
	pregnancy	112
12	Expected change in serum hCG levels in	
	first week of monitoring women at risk	
	for ectopic pregnancy	155
13	Comparison between both groups as	
	regard general data	252
14	Comparison between both groups as	
	regard type of cases	253
15	Comparison between both groups as	
	regard obstetric history	254
16	Comparison between both groups as	
	regard general condition and abdominal	
	examination	255
17	Comparison between both groups as	
	regard vaginal examination	256
18	Comparison between both groups as	
	regard Ultrasound examination	256
19	Comparison between both groups as	
	regard PIGF	257
20	Distributions of the studied cases as	
	regard pregnancy outcome in the study	
	group	257
21	Correlation between PIGF versus other	
	variables among cases	258
22	Correlation between PIGF versus other	
	variables among controls	259
23	Relation between PIGF versus history of	

	ectopic pregnancy among cases	259
24	Relation between PIGF versus type of	
	pregnancy termination among cases	260
25	Relation between PIGF versus general	
	condition among cases	260
26	Validity of PIGF in prediction of ectopic	
	pregnancy	261